Epigral Limited has released the audio recording of its conference call discussing the financial results for the first quarter of FY27. The recording is now accessible to investors and analysts via the company’s official website, providing a detailed review of the quarterly performance that was previously discussed during the live session on July 27, 2026. This disclosure ensures transparency and allows stakeholders who could not attend the live event to access management’s commentary on the company’s operational and financial standing.

The release of the audio file is in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule-III Part-A thereof. The original conference call was held on Monday, July 27, 2026, at 5:00 PM IST, where senior management addressed key performance indicators and strategic updates for Q1 FY27.

Conference Call Overview

The session was led by Epigral Limited’s senior leadership team, offering insights into the quarter’s outcomes. Key participants included Maulik Patel, Chairman and Managing Director; Kaushal Soparkar, Executive Director; Rakesh Agrawal, Chief Financial Officer; and Milind Kotecha, Investor Relations and Strategy. The event was coordinated by Emkay Global Financial Services Ltd., which facilitated the bridge line for domestic and international participants.

Accessing the Recording

Investors can now listen to the complete discussion through the direct link provided by the company. The audio file is hosted on Epigral Limited’s website under the results section, ensuring easy retrieval for record-keeping and analysis purposes.

The communication was signed off by Gaurang Trivedi, Company Secretary & Compliance Officer of Epigral Limited, confirming the authenticity and regulatory compliance of the disclosure. Investors are advised to refer to the official filings for detailed numerical data corresponding to the verbal commentary provided in the recording.

Epigral has incorporated a wholly owned subsidiary, Epigral Advanced Materials Limited, on July 7, 2026, to expand its manufacturing capabilities in the chemicals sector. The new entity has been established with a paid-up capital of ₹1,00,000, comprising 10,000 equity shares of ₹10 each. This strategic move aims to strengthen the company's presence in the advanced chemicals segment within India.

Subsidiary Details

Epigral Advanced Materials Limited is registered as a wholly owned subsidiary of Epigral Limited, making it a related party. The incorporation follows Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The subsidiary's primary objective is the manufacturing of chemicals, aligning with Epigral's broader business focus.

The consideration for the subscription was settled in cash. No specific governmental or regulatory approvals were required for the incorporation, as indicated in the filing submitted to the National Stock Exchange of India Limited and BSE Limited.